Modafinil — Eugeroic wakefulness agent (Schedule IV controlled substance)

Armodafinil (R-enantiomer, Nuvigil) has longer half-life (~15h vs ~12h for racemic modafinil) and is FDA-approved for same indications at lower doses (150-250mg). Off-label cognitive enhancement use is widespread but evidence is mixed — controlled studies show benefit in sleep-deprived individuals but minimal benefit in well-rested individuals. Modafinil significantly reduces efficacy of hormonal contraceptives via CYP3A4 induction — important warning for female patients.

نظرة عامة

هذه الصفحة جزء من مكتبة المركّبات المُصنَّفة بالأدلة في Hormonaly. جميع الادعاءات السريرية مرتبطة بمصادر علمية مُحكَّمة عبر خط أنابيب التحقق المزدوج للاستشهادات.

فئة المركّب

Eugeroic wakefulness agent (Schedule IV controlled substance)

آلية العمل

Precise mechanism incompletely understood but primarily involves dopamine transporter (DAT) inhibition — blocks dopamine reuptake similar to cocaine/amphetamines but with far lower abuse potential and no significant reinforcement. Also inhibits norepinephrine reuptake (NET), increases orexin/hypocretin system activity, and has weak histamine H3 antagonism. The orexin system activation is key to wakefulness maintenance without the jitteriness of amphetamines. Unlike methylphenidate, modafinil produces minimal dopamine flooding in nucleus accumbens (reward circuit) — explaining the lower addiction potential. Schedule IV (low abuse potential vs Schedule II amphetamines).

الوضع التنظيمي

FDA approved (Schedule IV controlled substance) — Provigil 1998

مستوى الأدلة

High — FDA-approved 1998; multiple RCTs across indications; well-established pharmacology